89bio (id:6464 ETNB)
8.76 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 5:18:47 PM)
Exchange closed, opens in 1 day 16 hours
3.67 USD (3.67%)
10.54 USD (10.54%)
10.89 USD (10.89%)
5.29 USD (5.29%)
12.60 USD (12.60%)
-72.13 USD (-72.13%)
-56.20 USD (-56.20%)
About 89bio
Market Capitalization 932.43M
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.
| Headquarters (address) |
142 Sansome Street San Francisco 94104 CA United States |
| Phone | 415 432 9270 |
| Website | https://www.89bio.com |
| Employees | 70 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | ETNB |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 7.00 - 16.63 |
| Market Capitalization | 932.43M |
| P/E trailing | -4.38 |
| P/E forward | -2.76 |
| Price/Book | 2.23 |
| Beta | 0.978 |
| EPS | -2.96 |
| EPS United States (ID:6, base:3402) | 24.25 |